NEBIVOLOL-D4;1-(6-fluorochroman-2-yl)-2-[[2-(6-fluorochroman-2-yl)-2-hydroxy-ethyl]amino]ethanol;Nibivolol;Nebivolol Impurity 6(rac-Nebivolol (Mixture of Diastereomers));2,2'-azanediylbis(1-(6-fluorochroman-2-yl)ethan-1-ol);rac-Nebivolol (Mixture of Diastereomers);1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino]ethanol;R-65824
Nebivolol is a highly selective, lipophilic β1-adrenergic receptor blocker used as an antihypertensive agent. It exhibits 290-fold greater selectivity for β1-adrenergic receptors over β2-adrenergic receptors, surpassing the specificity of other selective β1-blockers such as atenolol, metoprolol, and bisoprolol. Unlike conventional β-blockers, nebivolol does not cause bronchial or vascular smooth muscle constriction, lacks intrinsic sympathomimetic activity and membrane-stabilizing effects, and shows no affinity for serotonin, dopamine, or α1/α2-adrenergic receptors.
A key distinguishing feature of nebivolol is its ability to enhance nitric oxide (NO)-mediated physiological vasodilation, leading to endothelium-dependent coronary artery dilation and protection of cardiomyocytes against singlet oxygen-induced damage. This vasodilatory effect is endothelium-dependent, particularly for the levorotatory enantiomer, and is abolished upon endothelial removal or inhibition of NO synthase by L-NMMA.
Clinically administered as a racemic mixture of dextro- and levorotatory enantiomers in approximately equal proportions, nebivolol offers potent antihypertensive efficacy at low doses, convenient once-daily dosing, and a favorable safety profile with minimal adverse effects (e.g., headache, dizziness, fatigue, gastrointestinal disturbances, cough, pruritus, rash)—most of which are transient and rarely lead to treatment discontinuation. It does not cause orthostatic hypotension and seldom precipitates heart failure or severe bradycardia.
Thus, nebivolol represents a novel antihypertensive agent that combines potent β1-blockade with NO-mediated vasodilation, providing effective blood pressure control with fewer side effects compared to traditional β-blockers.